Stephens Consulting’s Novavax NVAX Stock Holding History

Stephens Consulting’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50	Closed	-$321	–	1718
2025 Q1	$321	Buy	+50	New	+$413	﹤0.01%	1449
2024 Q1	–	Sell	-1,000	Closed	-$4.8K	–	485
2023 Q4	$4.8K	Hold	1,000	–	–	﹤0.01%	375
2023 Q3	$7.24K	Hold	1,000	–	–	﹤0.01%	347
2023 Q2	$7.43K	Hold	1,000	–	–	﹤0.01%	347
2023 Q1	$6.93K	Sell	1,000 -2	-0.2%	-$18	﹤0.01%	365
2022 Q4	$10.3K	Hold	1,002	–	–	0.01%	293
2022 Q3	$18.2K	Sell	1,002 -1,000	-50%	-$43.3K	0.02%	260
2022 Q2	$103K	Sell	2,002 -10	-0.5%	-$518	0.08%	98
2022 Q1	$148K	Sell	2,012 -2,000	-50%	-$178K	0.12%	97
2021 Q4	$574K	Buy	+4,012	New	+$689K	0.48%	35

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Stephens Consulting's NVAX Position: Q2 2025 in Review

Stephens Consulting sold out of Novavax (NVAX) in Q2 2025, closing a stake of 50 shares — an estimated $321 sold.

Stephens Consulting first reported a position in NVAX in Q4 2021 and held it in 10 quarters. The position peaked at $574K in Q4 2021. 250 funds tracked by Wall St. Rank hold NVAX as of Q2 2025.

Stephens Consulting reported no remaining Novavax position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 50 Novavax shares in Q2 2025, an estimated $321.
Stephens Consulting first reported a position in Novavax in Q4 2021 and held it in 10 quarters.
Stephens Consulting's Novavax position peaked at $574K in Q4 2021.
250 funds tracked by Wall St. Rank held Novavax as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.